HER2 Gene Mutation Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0081068 (HER2 Gene Mutation)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT06123338A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric CancerTreatment